413 related articles for article (PubMed ID: 32292495)
1. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
2. miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin.
Du Q; Yuan Z; Huang X; Huang Y; Zhang J; Li R
Anticancer Drugs; 2022 Mar; 33(3):308-319. PubMed ID: 34924500
[TBL] [Abstract][Full Text] [Related]
3. SRGN Promotes Colorectal Cancer Metastasis as a Critical Downstream Target of HIF-1α.
Xu Y; Xu J; Yang Y; Zhu L; Li X; Zhao W
Cell Physiol Biochem; 2018; 48(6):2429-2440. PubMed ID: 30121667
[TBL] [Abstract][Full Text] [Related]
4. Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44.
Guo JY; Chiu CH; Wang MJ; Li FA; Chen JY
J Biomed Sci; 2020 Jan; 27(1):2. PubMed ID: 31898491
[TBL] [Abstract][Full Text] [Related]
5. Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer.
Zhu Y; Lam AKY; Shum DKY; Cui D; Zhang J; Yan DD; Li B; Xu WW; Lee NPY; Chan KT; Law S; Tsao SW; Cheung ALM
Theranostics; 2021; 11(6):2722-2741. PubMed ID: 33456569
[No Abstract] [Full Text] [Related]
6. Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway.
Xie J; Qi X; Wang Y; Yin X; Xu W; Han S; Cai Y; Han W
Cell Oncol (Dordr); 2021 Jun; 44(3):661-671. PubMed ID: 33651283
[TBL] [Abstract][Full Text] [Related]
7. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
9. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
Guo JY; Hsu HS; Tyan SW; Li FY; Shew JY; Lee WH; Chen JY
Oncogene; 2017 Apr; 36(17):2457-2471. PubMed ID: 27819672
[TBL] [Abstract][Full Text] [Related]
10. The Long Non-Coding RNA MALAT1 Enhances Ovarian Cancer Cell Stemness by Inhibiting YAP Translocation from Nucleus to Cytoplasm.
Wu X; Wang Y; Zhong W; Cheng H; Tian Z
Med Sci Monit; 2020 May; 26():e922012. PubMed ID: 32433460
[TBL] [Abstract][Full Text] [Related]
11. miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells.
Han X; Li M; Xu J; Fu J; Wang X; Wang J; Xia T; Wang S; Ma G
Int J Biol Sci; 2023; 19(1):89-103. PubMed ID: 36594100
[TBL] [Abstract][Full Text] [Related]
12. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
13. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
14. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
16. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness.
Kim T; Yang SJ; Hwang D; Song J; Kim M; Kyum Kim S; Kang K; Ahn J; Lee D; Kim MY; Kim S; Seung Koo J; Seok Koh S; Kim SY; Lim DS
Nat Commun; 2015 Dec; 6():10186. PubMed ID: 26671411
[TBL] [Abstract][Full Text] [Related]
17. The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells.
Yang CE; Lee WY; Cheng HW; Chung CH; Mi FL; Lin CW
Chem Biol Interact; 2019 Apr; 302():28-35. PubMed ID: 30703373
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
19. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
20. lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity.
Zhang Y; Fang Z; Guo X; Dong H; Zhou K; Huang Z; Xiao Z
J Cell Physiol; 2019 Aug; 234(10):18524-18534. PubMed ID: 30912138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
